Two of the Royal Society's 44 new fellows closely linked to UKCMRI

  • Date created: 20 May 2011

The Royal Society has elected 44 new fellows including two with close links to UKCMRI.

Sir Mark Walport was appointed Director of the Wellcome Trust in 2003. Before joining the Trust he was Professor of Medicine and Head of the Division of Medicine at Imperial College London, where he led a research group focusing on the immunology and genetics of rheumatic diseases. He received a knighthood in the 2009 New Year Honours List for services to medical research.

Dr Steve Gamblin is a group leader at the MRC National Institute for Medical Research in London - now part of the Francis Crick Institute. His research has provided critical insights into the fundamental mechanisms underlying cell signalling and disease processes. He uses a combination of structural, biophysical and functional studies to understand molecules involved in diseases such as influenza, diabetes and cancer.  In particular, his work has revealed how mutations in the influenza virus make one anti-viral drug more effective than another, thus helping define government policy on the stockpiling of anti-influenza drugs.

Sir Paul Nurse, President of the Royal Society and Chief Executive and Director of UKCMRI said: "It is a pleasure to welcome this year's new Fellows to the Royal Society. They join the ranks of the UK and Commonwealth's leading scientists, counting themselves among early Fellows such as Isaac Newton, Robert Boyle and Charles Darwin. The Society aims to expand the frontiers of knowledge by championing the development and use of science, mathematics, engineering and medicine for the benefit of humanity and the good of the planet. It is the contribution of excellent individuals such as these which makes this possible."

Related links

Sign up for our newsletters

Join our mailing lists to receive updates about our latest research and to hear about our free public events and exhibitions.  If you would like to find out more about how we manage your personal information please see our privacy policy.